Mission Therapeutics has appointed Dr Colin Goddard as its non-executive chairman, a role he will take up on January 1.
He first joined the Cambridge, UK-based drug discovery and development company as a non-executive director in July 2015.
Meanwhile, Mission Therapeutics’ current chairman Dr Michael Moore will continue to sit on the firm’s board and move into the role of deputy chairman.
Dr Moore said: “On behalf of the board, it gives me great pleasure to welcome Colin in his new role as the company progresses to the next phase of its evolution. I look forward to continuing to work with him and the board of directors as, together with an outstanding management team we continue to shape the company’s strategy.
“Colin’s timely accession extents the business reach of Mission commensurate with the significant advances in R&D.”
Prior to joining Mission, Dr Goddard had served as chief executive officer of OSI Pharmaceuticals since 1998, after joining the firm as a research scientist in 1989.
After OSI’s acquisition by Astellas in June 2010 for $4bn Dr Goddard served as chairman and CEO of US-based biotech company BlinkBio.